While the bulk of solid tumour studies, including NSCLC, demonstrated a potentially worse prognosis for the patients with high tumour-infiltrating Foxp3+CD4+ T cell levels, others, to the contrary, represented results with better prognoses for patients with a high level of tumour stroma infiltrating Foxp3 +CD4+ T cells. The gene discussed is FOXP3; the disease is neoplasm.